CClinicalTrials.gg
CompletedNCT03429140HEALRUpdated Sep 13, 2022

Early Anti-inflammatory Treatment in Patients With Acute ACL Tear and Painful Effusions

An Early Phase 1 interventional study of Gel-One and Saline Placebo in Anterior Cruciate Ligament, sponsored by Cale Jacobs, PhD. Completed at 1 site in United States. Open to participants aged 14 Years to 33 Years. Per ClinicalTrials.gov, last updated 2022-09-13.

Sponsored by Cale Jacobs, PhD · Early Phase 1, Interventional, and Treatment

Phase
Early Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
14 Years to 33 Years
Sex
All
01

Study summary

This research study is designed to allow the investigator to answer many questions about the reasons why anterior cruciate ligament (ACL) injury leads to knee pain and disability and osteoarthritis.

The purpose of this research is to gather information on how safe and effective Gel-One is in alleviating knee pain following ACL surgery.

Read the detailed description

This is a single-center, placebo-controlled, double-blinded, randomized controlled trial.

This trial will be conducted at the University of Kentucky's Orthopaedic and Sports Medicine Center (Turfland Facility), with subjects being recruited from the patient populations of UK's Sports Medicine surgeons (Drs. Christian Lattermann, Darren Johnson, Mary Lloyd Ireland, and Scott Mair) during regularly schedule office visits.

After providing informed consent, subjects will be randomized into one of two groups, and there will be 19 subjects per group. All groups will receive standard of care aspiration and triamcinolone injection (40mg, Kenalog) within 1-10 days after ACL injury. The subjects will undergo initial standard of care pre-habilitation as deemed necessary by the surgeon and will undergo ACL reconstruction surgery. Knee aspiration will be performed 7-10 days after ACL reconstruction surgery and the patients will be randomized into 1 of 2 groups:

  • Group 1: will receive injection of Gel-One (3ml 30mg Hyaluronan)
  • Group 2: will receive an injection of 3ml of a saline placebo

Knee Aspiration: All subjects will undergo a total of four aspirations.

Visit Schedule and Procedures:

Visit 1 Screening (1-10 days post injury): Upon arriving at the clinic potential subjects will have the following assessments: range of motion, knee instability (Lachman's test) and standardized Flexion weight bearing x-rays, all of which are the standard of care for a patient with a suspected ACL injury. After providing informed consent to participate in the study, subjects will be asked to fill in standard questionnaires.

Collection of urine and 10 cc of blood for laboratory testing, partial Medical history, concomitant medications, demographic information, body mass index (BMI) measurement, smoking status, and questions will be collected. Scheduling for study-related magnet resonance imaging (MRI) scans.

Visit 2 (day of surgery)

  • Lab specimens collected (urine and 10cc of blood)
  • Pain Questionnaires administered prior to surgery
  • Knee aspiration (in the operating room under anesthesia, both knees)
  • Patient reported outcomes (PROs) administered prior to surgery

Visit 3 (1-2 weeks post surgery)

  • Pain Questionnaires administered
  • Lab tests (urine and 10cc of blood)
  • Randomization into group 1 or 2
  • Knee aspiration and administration of either 3ml of saline(placebo) or Hyaluronan (study drug)

Visit 4 (4-6 weeks post surgery)

  • Pain Questionnaire administered
  • Knee aspiration and lab specimens collected
  • Patient reported outcomes (PROs) administered

Visit 5 (6 months follow-up/Early Termination Visit)

  • Patient reported outcomes (PROs) administered
  • Pain Questionnaires administered
  • Functional laboratory testing

Visit 6 (12 months follow-up/Early Termination Visit)

  • Patient reported outcomes (PROs) administered
  • Pain Questionnaires administered
  • Functional laboratory testing
  • MRI scan

There are no costs associated with either the study medications and study-specific laboratory and imaging analyses. Either the participant or their insurance company, Medicare or Medicaid will be responsible for the costs of all care and treatment a participant receives during this study that they would normally receive for their condition. These are costs that are considered medically reasonable and necessary and will be part of the care a patient would receive if they did not take part in this study.

02

Conditions studied

  • Anterior Cruciate Ligament
03

Who can participate

Ages eligible
14 Years to 33 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • 14-33 years of age
  • Currently participating in a sporting activity
  • ACL injury occurred while playing in a sporting activity
  • Normal contralateral knee status
  • Documentation of closed growth plates as noted on the screening x-rays

Exclusion criteria

Exclusion Criteria:

  • Underlying inflammatory disease (i.e. Rheumatoid Arthritis, Psoriatic Arthritis etc)
  • Currently have any infections, including infection of the skin, or have signs and symptoms of an infection, including fever
  • Have a disease that weakens your immune system such as diabetes, cancer, HIV or AIDs
  • Other major medical condition requiring treatment with immunosuppressant or modulating drugs
  • A history of chronic use of non-steroidal anti-inflammatory drugs
  • Received corticosteroid injections into the injured knee within three months of enrollment
  • History of allergic reaction to hyaluronan injections
  • Previous exposure or allergic reaction to Kenalog®
  • Prior knee surgery (Ipsilateral or contralateral)
  • Have received any investigational drug with 4 weeks of study Visit 1
04

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Group 1 - Gel-One

    Gel-One (3ml/30 mg Hyaluronan) one time injection at visit 3

    Drug: Gel-One

  • Placebo comparator
    Group 1 - Saline Placebo

    3 ml saline placebo one time injection at visit 3

    Other: Saline Placebo

Interventions

  • DrugGel-One

    an injection of Gel-One® (hyaluronan, 3 mL) 1-2 weeks after ACL surgery

  • OtherSaline Placebo

    a placebo injection (saline, 3 mL) 1-2 weeks after ACL surgery

05

What researchers measure

Primary outcomes

  1. Change in KOOS score over time

    Knee Injury and Osteoarthritis Outcome Score (KOOS) symptoms

    Time frame: 12 months

Secondary outcomes

  1. Change in CTX-II pre and post surgery

    CTX -II ELISA measurements

    Time frame: up to 4 weeks

Other outcomes

  1. MRIT1rho measurement of articular cartilage

    MRI measurement

    Time frame: 12 months

  2. Number of participants with adverse events that are related to treatment.

    Protocol safety questionnaires and SAE/AE reporting

    Time frame: 12 months

06

Study locations

1 site
  • UK Healthcare at Turfland
    Lexington, Kentucky 40504, United States
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03429140
Lead sponsor
Cale Jacobs, PhD
Responsible party
Cale Jacobs, PhD (Principal Investigator, University of Kentucky) — Sponsor-investigator
First posted
Feb 12, 2018
Start date
Apr 6, 2017
Primary completion
Jun 23, 2019
Completion
Jun 23, 2019
Last update
Sep 13, 2022

Study contacts

Cale Jacobs, PhD
principal investigator · University of Kentucky

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion